EU External Trade - PHARMACEUTICAL PRODUCTS, Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale

Extra-EU sourcing of PHARMACEUTICAL PRODUCTS, Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale is highly concentrated. 🇺🇸 United States captures 56.4% of imports (€6.1B), followed by 🇨🇭 Switzerland (18.4%). With an HHI of 3605, this Concentrated market exposes the EU to supply dependency risks.

The main extra-EU export markets for PHARMACEUTICAL PRODUCTS, Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale are 🇺🇸 United States, 🇷🇺 Russia, 🇨🇭 Switzerland. 🇺🇸 United States absorbs 42.3% of European exports (€4.8B).

Within the EU, the leading importers of PHARMACEUTICAL PRODUCTS, Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale are 🇧🇪 Belgium, 🇩🇪 Germany, 🇮🇪 Ireland. 🇧🇪 Belgium accounts for 21.7% of EU imports.

In 2025, imports were falling sharply (-15.9%) and exports declining (-6.1%) compared to the previous year.